ArticleAmerican heart journal plus : cardiology research and practice2026
Association between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magnesium sulfate is commonly administered in acute heart failure (AHF). We investigated the association between early intravenous magnesium sulfate and mortality across baseline systemic immune-inflammation index (SII) strata in critically ill patients with AHF. Methods: We conducted a retrospective study using the MIMIC-IV database of critically ill patients with AHF. Early intravenous magnesium sulfate was defined as treatment initiated from 6 h before to 24 h after intensive care unit admission. SII was categorized into quartiles. The primary and secondary outcomes were 30-day and 90-day all-cause mortality. Multivariable Cox regression, restricted cubic spline, and sensitivity analyses were performed. Results: Among 4293 patients, 1561 (36.4%) received intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day (adjusted hazard ratio [aHR] 0.68, 95% CI 0.56-0.82) and 90-day mortality (aHR 0.74, 95% CI 0.63-0.86). For 30-day mortality, multivariable Cox regression demonstrated significant associations in the lowest (aHR 0.64, 95% CI 0.43-0.95) and highest (aHR 0.52, 95% CI 0.36-0.75) SII quartiles, whereas no significant associations were identified in the intermediate quartiles. Comparable patterns were observed for 90-day mortality. Restricted cubic spline analyses showed visual separation between treatment groups at the extremes of the SII distribution, although formal interaction testing was not significant. Sensitivity analyses consistently reproduced the association in the highest SII quartile. Conclusions: Stratified analyses suggested that the association between early magnesium sulfate administration and lower mortality was most evident in the highest SII quartile and less consistent in the lowest quartile. These findings are hypothesis-generating and require prospective validation. Trial registration: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.